45It should be added that the fact that, in the case in the main proceedings, the direct beneficiary of the supplies of the medicinal products in question was not the State health insurance agency which subsequently reimbursed the amount of the subsidy to the pharmacy but the insured persons themselves who paid the subsidised price to the pharmacy, is not such as to break the direct link between the supply of services made and the consideration received (see, to that effect, judgment of 20 December 2017, Boehringer Ingelheim Pharma, C‑462/16, EU:C:2017:1006, paragraph 40).
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.